Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03059173Phase 3Recruiting

Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome

Role: collaborator

NCT04853069Phase 2Unknown

Oestrogen Treatment for COVID-19 Symptoms

Role: collaborator

NCT01786473Phase 3Unknown

Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism

Role: lead

All 3 trials loaded